All News
Filter News
Found 155 articles
-
ObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in November
10/31/2017
Management will host an investment community conference call at 8:00 a.m. ET.
-
ObsEva Announces $60 Million Private Placement With Existing And New Investors
10/10/2017
-
ObsEva Announces Presentation Related To Its PGF2alpha Receptor Antagonist At ACCP 2017 Annual Meeting
9/11/2017
-
ObsEva Announces The Completion Of Patient Recruitment In The IMPLANT2 Phase III Clinical Trial In Assisted Reproductive Technology Ahead Of Schedule
9/6/2017
-
ObsEva Reports Second Quarter 2017 Financial Results And Provides Business Update
8/16/2017
-
ObsEva To Hold Second Quarter 2017 Financial Results/Business Update Call On August 15, 2017 And Present At Wedbush Pacgrow Healthcare Conference In NYC On August 16, 2017
8/7/2017
-
Intellia Names Moncef Slaoui, Ph.D. And Frank Verwiel, M.D. To Its Board Of Directors And Establishes A Science And Technology Committee
7/24/2017
-
Intellia Names Moncef Slaoui, Ph.D. And Frank Verwiel, M.D. To Its Board Of Directors And Establishes A Science And Technology Committee
7/24/2017
-
ObsEva Announces Presentations Related To Its Assisted Reproductive Technology (ART) And Pre-Term Labor (PTL) Development Programs At ESHRE 2017 Annual Meeting
6/29/2017
-
Ovid Therapeutics Appoints Barbara G. Duncan To Its Board Of Directors
6/15/2017
-
ObsEva Announces The Completion Of A Phase I PK/PD Clinical Trial Evaluating Different Doses Of OBE2109 And Add-Back Therapy
6/7/2017
-
Dr Nanna Lüneborg, Principal Of Novo Ventures, Joins Inventiva's Board
5/30/2017
-
ObsEva Announces The Completion Of A Phase I Drug-Drug Interaction Study With OBE022
5/18/2017
-
ObsEva Reports First Quarter 2017 Financial Results and Business Update
5/18/2017
-
ObsEva To Hold First Quarter 2017 Financial Results And Business Update Call On Thursday, May 18, 2017
5/11/2017
-
ObsEva Initiates Phase III Clinical Program For OBE2109 In Uterine Fibroids
4/25/2017
-
ObsEva To Present Pharmacology Results Demonstrating OBE022 Exerts A Synergistic Effect In Combination With Standard Of Care In Animal Model For Preterm Labor
3/17/2017
-
ObsEva Starts Phase III Clinical Program For Nolasiban In ART
3/7/2017
-
Women's Health Biotech ObsEva to Open Up U.S. HQ in Boston After $97 Million IPO
1/30/2017
-
Cambridge Biotech Jounce Bounces on the IPO Scene, Raises $102 Million
1/27/2017